Published in final edited form as:

Nat Med. 2015 March ; 21(3): 211. doi:10.1038/nm.3823.

Timing is everything for compassionate use of delamanid

Clifton E. Barry III

Chief, Tuberculosis Research Section, National Institute of Allergy and Infectious Disease,
National Institutes of Health, Bethesda, MD

To the Editor:

Nature Medicine recently published a News article¹ describing difficulties in early patient access to Deltyba (delamanid), a new antituberculosis drug that received conditional approval by the European Medicines Agency late in 2013 that I believe requires some clarification. The title of the story refers to the drug's developer, Otsuka Holdings, as a "Nutraceutical Company". Otsuka Pharmaceuticals, which is owned by Otsuka Holdings, is the 20th largest pharmaceutical company in the world by total sales and produces pharmaceuticals such as the blockbuster antipsychotic Abilify®.

It is worth noting that both Sirturo (bedaquiline), the drug the Californian patient Gary in the story was already receiving, and Deltyba – cause a significant prolongation of the cardiac QT interval in patients receiving them^{2,3} and there is reason to be very concerned that the two together may amplify this effect. There is also some reason to believe from preclinical animal data that the two drugs may actually antagonize each other's action⁴. These issues are among those that led the World Health Organization in 2013 to issue interim guidance for Deltyba that did not recommend the use of this agent in combination with Sirturo until additional studies had been done⁵.

The article focuses on Otsuka's compassionate use program and an individual patient's heartbreaking story. Patient access to new medications in early clinical development is always a difficult and sensitive issue. Deltyba is approved for use in adults with MDR-TB in Europe but the US Food and Drug Administration has not yet approved it. The European Respiratory Society and the World Health Organization implemented a virtual consulting system for difficult to manage TB cases in 2013⁶. This "consilium" played an important role in developing Otsuka's compassionate use program and leading TB physicians have agreed that the overall strategy was appropriate⁷.

Nearly 45% (213/481) of patients in Otsuka's phase 2B trial of Deltyba received a 6-month treatment extension that amounted to compassionate use. In addition, Otsuka has also launched a phase III trial and completed randomization of 511 patients, about 340 of whom are receiving Deltyba ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT01424670) ID# NCT01424670).

Finally, the article compares the number of patients treated through the compassionate-use program of Sirturo and Deltyba, but fails to note that Sirturo was approved in the US in 2012, while Deltyba was only approved in the EU late in 2013 and is still not approved in the United States. Everyone wants to ensure that patients with life-threatening drug-resistant TB gain access to these new therapeutic options as quickly as possible, but it must be done

safely and in a controlled setting. Otsuka has made a huge contribution to global TB control in bringing this new drug forward. We cannot, and should not, risk compromising patient safety by rushing forward carelessly. There will be a time for vastly expanded access to this new agent, but that time is not now.

References

1. Gruber K *Nat. Med* 21, 103(2015). [PubMed: 25642939]
2. Guglielmetti L, Le Dû D, Jachym M, Henry B, Martin D, Caumes E, Veziris N, Métivier N, Robert J; MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort. *Clin Infect Dis* 60,188–94(2015). [PubMed: 25320286]
3. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD *N Engl J Med* 366, 2151–60(2012). [PubMed: 22670901]
4. Tasneen R, Li SY, Peloquin CA, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger EL *Antimicrob Agents Chemother.* 55, 5485–92(2011). [PubMed: 21930883]
5. The use of delamanid in the treatment of multidrug-resistant tuberculosis Interim policy guidance (WHO/HTM/TB/2014.23). Geneva, World Health Organization 2014.
6. <https://www.tbconsilium.org/>
7. Esposito S, D'Ambrosio L, Tadolini M, Schaaf HS, Caminero Luna J, Marais B, Centis R, Dara M, Matteelli A, Blasi F, Migliori GB *Eur Respir J* 44, 811–5(2014). [PubMed: 24833763]